Current oncology最新文献

{"title":"Serum Free Light Chains in Lymphoma: A Phenotype-First Framework for Biological Interpretation, Analytical Control, and Clinical Use.","authors":"Michele Bibas, Barbara Amoroso, Elena Matteini, Andrea Antinori, Valentina Mazzotta","doi":"10.3390/curroncol33100580","DOIUrl":"10.3390/curroncol33100580","url":null,"abstract":"<p><p>Serum free light chains (sFLC) reflect immunoglobulin production and renal clearance, making abnormal results biologically heterogeneous in lymphoma. We reviewed clinical, translational, and analytical evidence using a documented PubMed search. Three operational patterns should be distinguished: monoclonal-pattern elevation, polyclonal-pattern elevation, and ratio-only abnormality. The kappa-plus-lambda concentration is an overlapping measure of total circulating burden rather than a fourth exclusive phenotype. In diffuse large B-cell lymphoma, some cohorts reported International Prognostic Index-adjusted associations and improved model discrimination, whereas other studies did not confirm independent prognostic value. Evidence in classical Hodgkin lymphoma and chronic lymphocytic leukemia also depends on endpoint, adjustment, and treatment setting. Prediagnostic associations in human immunodeficiency virus infection, transplantation, and population cohorts do not establish screening utility. In Waldenström macroglobulinemia, involved-chain kinetics may supplement established assessment in selected patients, although clinical benefit from sFLC-directed management has not been demonstrated. Historical treatment regimens, overlapping cohorts, inconsistent renal adjustment, assay differences, and limited external validation restrict transferability. The proposed framework integrates phenotype, renal function, assay, sampling time, and disease context. It is an interpretive proposal, not a validated prognostic score or treatment algorithm.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mediating Role of Illness Perception Between Psychological Capital and Subjective Well-Being in Breast Cancer Patients: A Cross-Sectional Study.","authors":"Ming Liu, Ying Zhang, Chengbin Xu, Yu Liu, Yin Wang, Yaxi Wang, Zhuzhu Wang, Jingfang Hong","doi":"10.3390/curroncol33100581","DOIUrl":"10.3390/curroncol33100581","url":null,"abstract":"<p><p>Subjective well-being is increasingly recognized as a key health outcome among breast cancer patients, yet the psychological mechanisms that enhance it remain insufficiently understood. This study aimed to describe the levels of psychological capital, illness perception, and subjective well-being in breast cancer patients, examine their correlations, and test the mediating role of illness perception in the association between psychological capital and subjective well-being. A cross-sectional study was conducted among 256 breast cancer patients recruited by convenience sampling from a provincial tertiary hospital in Hefei, China. Patients were assessed using a self-designed general information questionnaire, the Positive Psychological Capital Questionnaire, the Brief Illness Perception Questionnaire, and the General Well-being Schedule. Data were analyzed using SPSS and PROCESS macro. The mean scores of psychological capital, illness perception, and subjective well-being were 102.31 ± 26.32, 38.54 ± 6.56, and 66.34 ± 14.07, respectively. Pearson's correlation analysis showed that psychological capital was negatively correlated with illness perception (<i>r</i> = -0.648, <i>p</i> < 0.01), but positively correlated with subjective well-being (<i>r</i> = 0.620, <i>p</i> < 0.01). Illness perception was negatively correlated with subjective well-being (<i>r</i> = -0.792, <i>p</i> < 0.01). Mediation analysis showed that illness perception partially mediated the association between psychological capital and subjective well-being (B = 0.243, 95% CI: 0.194-0.295), accounting for 62.48% of the total effect (B = 0.388, 95% CI: 0.330-0.446). This study underscores the mediating role of illness perception in the association between psychological capital and subjective well-being among breast cancer patients. Reducing negative illness perceptions and enhancing psychological capital may help improve patients' subjective well-being.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation Between iNKT Cells and Malignant Tumors: A Meta-Analysis.","authors":"Chendi Liang, Xiaoxia Wang, Jun Lu","doi":"10.3390/curroncol33100579","DOIUrl":"10.3390/curroncol33100579","url":null,"abstract":"<p><p>Cancer is one of the major global health problems, with increasing numbers of new cases and deaths each year. This highlights the urgency of effective treatment. The iNKT cells act as a special subset of T cells with potent anti-tumor effects. Therefore, the correlation between iNKT cells and cancer will be evaluated in terms of frequency, prognosis, and efficacy in this study. A total of 62 studies involving 1076 healthy controls and 2453 cancer patients were included in this meta-analysis. The meta-analysis showed that the number of circulating iNKT cells was significantly higher in healthy controls than in cancer patients, as well as the frequency of iNKT cells in circulating T cells and mononuclear cells. At the same time, the frequency of iNKT cells in T cells was significantly higher in non-tumor tissues than in tumor tissues. In terms of prognosis, the higher frequency of iNKT cells in peripheral blood or tumor tissues of cancer patients was associated with improved overall survival (OS) and relapse-free survival (RFS). Regarding the efficacy of iNKT cell-related therapies, the objective response rate was 3%, and the disease control rate was 49%. In conclusion, iNKT cells were significantly reduced in cancer patients, and the higher frequency of iNKT cells was associated with a favorable prognosis in these patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic CT-Based Palliative Radiotherapy Using kV Image Verification: A Prospective Feasibility Study.","authors":"Kelly Wei, Jason Hui, Bradford Gill, Sheri Grahame, Alexandra Guytingco, Wei Liu, Mitchell Liu, Eric Berthelet, Srinivas Raman, Elaine Wai, Shilo Lefresne","doi":"10.3390/curroncol33100577","DOIUrl":"10.3390/curroncol33100577","url":null,"abstract":"<p><p>Patients receiving palliative radiotherapy (PRT) often experience substantial symptom burden and may face challenges attending multiple hospital visits. Planning treatment using an existing diagnostic computed tomography (dCT) scan instead of a dedicated computed tomography (CT) simulation may improve access to timely care. This prospective feasibility study evaluated a dCT-based planning workflow using kilovoltage (kV) image verification for patients with bone metastases, with potential applicability to resource-limited settings. Ten patients receiving conventional PRT (8 Gy in 1 fraction or 20 Gy in 5 fractions) with an eligible dCT acquired within 28 days were enrolled. As part of this feasibility study, all patients also underwent standard CT simulation, which served as the dosimetric comparator and fallback treatment pathway. Radiotherapy plans generated on dCT and CT simulation scans were compared for dosimetric quality, while treatment deliverability, patient satisfaction, and estimated carbon emissions were assessed. Seven of ten patients were successfully treated using the dCT workflow. The three remaining patients were transitioned to standard CT simulation treatments due to an uncorrectable dCT image rotation in the planning software (<i>n</i> = 1), scheduling constraints (<i>n</i> = 1), and a larger-than-anticipated difference in patient separation on the treatment unit (<i>n</i> = 1). Target coverage and organ-at-risk doses were comparable between dCT and CT simulation plans, satisfaction among dCT-treated patients was high, and potential avoidance of CT simulation was estimated to reduce carbon emissions by approximately 10 kg carbon dioxide equivalent (CO₂e) per patient. These findings demonstrate that dCT-based planning with kV image verification is feasible, provides dosimetry comparable to conventional CT simulation, and warrants further evaluation as a strategy to improve access to timely PRT while reducing healthcare resource use and environmental impact.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies.","authors":"Anastasia Chambers, Morgan Reeves, Abhishek Shrestha, Siri Yarrapatni, Sergio Duarte, Ali Zarrinpar","doi":"10.3390/curroncol33100576","DOIUrl":"10.3390/curroncol33100576","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with poor patient outcomes largely attributable to late diagnosis and the frequent development of therapeutic resistance. Although advances in chemotherapy, targeted therapies, immunotherapy, and combination regimens have improved treatment options, durable clinical responses remain limited. This review synthesizes current evidence on the role of β-catenin signaling in HCC progression and therapeutic resistance, emphasizing the molecular mechanisms underlying aberrant pathway activation and its interactions with other oncogenic signaling networks. The review examines how constitutive β-catenin activation promotes tumor growth, cancer stem cell maintenance, metabolic reprogramming, immune evasion, and resistance to chemotherapy, targeted therapies, and immune checkpoint inhibitors. In addition, emerging therapeutic strategies targeting β-catenin are discussed, including inhibition of β-catenin transcriptional activity, modulation of upstream Wnt signaling, direct suppression of <i>CTNNB1</i> expression using nucleic acid-based approaches, and interventions targeting the immune and metabolic consequences of pathway activation. Collectively, the evidence identifies β-catenin as a central mediator of HCC progression and treatment resistance while highlighting its potential as a therapeutic target. A deeper understanding of β-catenin-driven mechanisms may facilitate the development of more effective therapeutic strategies and improve clinical outcomes for patients with HCC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paired Tissue and Plasma Comprehensive Genomic Profiling in Advanced Solid Tumors: A Retrospective Study from India.","authors":"Ankur Bahl, Nitesh Rohatgi, Suman S Karanth, Aakriti Aggarwal, Rohit Bharat, Nippun Sandhir","doi":"10.3390/curroncol33100575","DOIUrl":"10.3390/curroncol33100575","url":null,"abstract":"<p><strong>Background: </strong>Tissue and plasma comprehensive genomic profiling (CGP) sample different compartments and may yield nonoverlapping clinically relevant findings. We assessed the added patient-level yield of paired testing in a pan-cancer cohort from India.</p><p><strong>Methods: </strong>This retrospective, single-institution study included patients with stage IV solid tumors who underwent paired tissue and plasma CGP between November 2022 and October 2024. The primary endpoint was detection in a patient of an OncoKB Level 1 or Level 2 or R1 alteration, high tumor mutational burden, or microsatellite instability. Molecularly informed therapy and laboratory turnaround time were assessed descriptively.</p><p><strong>Results: </strong>Of 158 patients, 123 matched evaluable pairs were analyzed. Either modality detected a clinically relevant finding in 46 of 123 patients (37.4%; 95% confidence interval, 29.4-46.2%): tissue CGP in 33 (26.8%), plasma CGP in 35 (28.5%), both in 22 (17.9%), tissue only in 11 (8.9%) and plasma only in 13 (10.6%). This complementarity remained bidirectional across exploratory analyses, including a subgroup that excluded non-small cell lung cancer (33.0%), all 139 technically successful pairs (33.8%), all 158 paired sample sets (32.3%), and even when the endpoint was restricted to OncoKB alterations (22.0%). Among 91 patients with therapy-alignment data, 25 (27.5%) received molecularly informed therapy. Median laboratory turnaround time was 7 days for plasma and 13 days for tissue CGP.</p><p><strong>Conclusions: </strong>Tissue and plasma CGP were complementary rather than interchangeable in this selected cohort: either modality alone would have missed clinically relevant findings. Whether this improves outcomes is untested; prospective studies linking testing strategy to treatment delivery and survival are needed.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.","authors":"Seoung Hoon Kim, Byeong Ho An, Jin A Lee, Go Woon Jeong","doi":"10.3390/curroncol33100578","DOIUrl":"10.3390/curroncol33100578","url":null,"abstract":"<p><strong>Background: </strong>Machine perfusion has emerged as a promising strategy to attenuate ischemia-reperfusion injury during liver transplantation (LT). However, its impact on hepatocellular carcinoma (HCC) recurrence and post-transplant oncologic outcomes remains uncertain. We performed a systematic review and meta-analysis evaluating the association between machine perfusion and oncologic outcomes after LT for HCC.</p><p><strong>Methods: </strong>A systematic literature search of PubMed/MEDLINE, Embase, and Web of Science was conducted from database inception to May 2026. Comparative clinical studies evaluating machine perfusion and oncologic outcomes after LT for HCC were included. The primary outcome was recurrence-free survival (RFS). Secondary outcomes included HCC recurrence, early recurrence, overall survival (OS), and graft-related outcomes. Risk of bias was assessed using the ROBINS-I tool. Random-effects meta-analyses were performed when appropriate.</p><p><strong>Results: </strong>Six comparative clinical studies involving HCC recipients undergoing LT were included. All studies were observational, and no randomized controlled trial was identified. Three studies were judged to have a moderate risk of bias and three were judged to have a serious risk of bias. In the primary RFS meta-analysis, machine perfusion was associated with a numerically lower risk of recurrence or death, although the pooled estimate did not reach statistical significance (HR 0.34, 95% CI 0.07-1.77; <i>p</i> = 0.20). The binary recurrence analysis also demonstrated a numerically lower risk of HCC recurrence after machine perfusion (RR 0.40, 95% CI 0.13-1.20; <i>p</i> = 0.10). Several studies reported favorable associations between machine perfusion and early recurrence, while large adjusted cohorts reported associations with improved RFS and OS. Machine perfusion was generally associated with lower markers of ischemia-reperfusion injury, including postoperative aminotransferase release.</p><p><strong>Conclusions: </strong>Current evidence suggests a potential favorable association between machine perfusion and oncologic outcomes after LT for HCC. However, the pooled estimates from the primary analyses were not statistically significant, and the evidence remains limited by the small number of studies, observational designs, heterogeneity, and potential cohort overlap. Further prospective studies are required before an oncologic benefit of machine perfusion can be established.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13702942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.","authors":"Nolan Holley, Syed Ahmad, Gary Monroe, Sonya Brooks, Pranathi Tella, Sobha Kurian, Brijesh Patel","doi":"10.3390/curroncol33100574","DOIUrl":"10.3390/curroncol33100574","url":null,"abstract":"<p><p><b>Background/Aim</b>: The addition of an immune-checkpoint inhibitor (ICI) to chemotherapy improves outcomes in both early-stage and metastatic triple-negative breast cancer (TNBC). However, ICIs are associated with immune-related adverse events (irAEs), such as cardiotoxicity, raising concerns for patients receiving both anthracyclines and ICIs. We sought to determine if combining anthracycline and ICI in TNBC is associated with greater cardiotoxicity than anthracycline alone. <b>Methods</b>: A retrospective cohort study was conducted at a large academic center. Two cohorts were analyzed: anthracycline plus ICI and anthracycline alone. Demographics, comorbidities, medications, cardiac imaging, and outcomes were reviewed. Time to adverse cardiac events were compared. <b>Results</b>: A total of 382 patients were included: 297 received anthracyclines without ICI, and 85 received both. There were no major differences in baseline characteristics. The rate of acute cardiac events was 3.4% in the anthracycline-alone cohort and 3.5% in the anthracycline-plus-ICI cohort (<i>p</i> > 0.99) over a median of 1232 days of follow up (median of 1336 days in the anthracycline only group; median of 704 days in the ICI group). No significant differences in acute heart failure, acute coronary syndrome, myocarditis, or pericardial effusion were observed. Kaplan-Meier analysis showed no significant difference in cardiac event-free survival (<i>p</i> = 0.60). Furthermore, there was no significant difference in time to cardiac events between the two groups following competing risk analysis when accounting for both prior coronary artery disease (HR = 1.32, 95% CI: [0.42, 4.14], <i>p</i> = 0.64) and age (HR = 1.64, 95% CI: [0.52, 5.19], <i>p</i> = 0.40). <b>Conclusions</b>: This single-institution analysis did not identify a significant increase in cardiotoxicity with the addition of an ICI to anthracycline therapy in patients with TNBC. Active surveillance for cardiotoxicities should continue in patients receiving ICI in addition to anthracycline therapy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spiritual-Religious Profiles and Psychological Distress in Romanian Patients with Cancer.","authors":"Dana Sonia Nagy, Vlad-Norin Vornicu, Alina-Gabriela Negru, Alina Doina Tănase, Serban Mircea Negru","doi":"10.3390/curroncol33100573","DOIUrl":"10.3390/curroncol33100573","url":null,"abstract":"<p><p><b>Background/Objectives:</b> Religious engagement may coexist with low existential well-being. We identified spiritual-religious profiles in Romanian patients with cancer, assessed their associations with distress and quality of life, and evaluated spirituality's incremental predictive value. <b>Methods:</b> This single-centre cross-sectional study included 175 adults with cancer. Latent profile analysis used FACIT-Sp Meaning, Peace, and Faith, Religious Commitment Inventory-10, and service attendance. Clinically significant distress was defined as Hospital Anxiety and Depression Scale anxiety or depression scores ≥8. Adjusted regression and a six-predictor logistic model with bootstrap internal validation were used. <b>Results:</b> Three profiles emerged: low spiritual-religious resource (<i>n</i> = 61), religiously engaged but existentially unsettled (<i>n</i> = 52), and integrated spiritual-religious resource (<i>n</i> = 62). Distress prevalence was 68.9%, 61.5%, and 25.8%, respectively (<i>p</i> < 0.001). Compared with the low-resource profile, the integrated profile had lower adjusted odds of distress (OR 0.19, 95% CI 0.08-0.44), higher global quality of life (adjusted difference 14.1 points, 95% CI 4.4-23.8), and lower symptom burden (-11.8 points, 95% CI -18.6 to -5.0). The full model had an apparent AUC of 0.816 (95% CI 0.748-0.875) and an optimism-corrected AUC of 0.789. Its AUC exceeded that of the clinical-only model by 0.064 (95% CI 0.008-0.12; <i>p</i> = 0.023). <b>Conclusions:</b> Religious involvement alone did not indicate resolved spiritual needs. Inner peace may improve distress risk assessment, although prospective external validation is required.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathological and MRI-Based Infiltrative Markers Show Distinct Associations with Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma.","authors":"Akane Ariga, Yuki Funauchi, Kyoko Yamashita, Masanori Saito, Keiko Hayakawa, Taisuke Tanizawa, Norio Kurosawa, Toshitaka Yoshii, Keisuke Ae","doi":"10.3390/curroncol33100572","DOIUrl":"10.3390/curroncol33100572","url":null,"abstract":"<p><p>Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) frequently exhibit infiltrative growth, but whether pathological and magnetic resonance imaging (MRI)-based findings represent the same tumor characteristics remain unclear. We examined the relationships among report-documented pathological infiltration (PI), MRI-defined diffuse infiltration (DI), and radiological infiltration (RI) based on the tail sign, and explored their associations with oncologic outcomes. This single-center retrospective cohort study included 68 treatment-naïve patients with primary UPS or MFS without distant or lymph-node metastasis at presentation who underwent curative-intent resection. The primary outcome was progression-free survival (PFS), with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS) evaluated as secondary outcomes. Time-to-event associations were evaluated using Firth's penalized Cox regression with parsimonious covariate adjustment and sensitivity analyses restricted to patients with R0 resection. DI, RI, and PI were observed in 75.0%, 76.5%, and 60.3% of patients, respectively. RI positivity was more frequent among patients with PI, whereas DI showed no clear relationship with PI or RI. In an exploratory multivariable model, DI (hazard ratio [HR], 3.30; 95% confidence interval [CI], 1.05-16.51; <i>p</i> = 0.040) and RI (HR, 4.26; 95% CI, 1.31-22.29; <i>p</i> = 0.013) were associated with worse PFS. Local recurrences occurred only in patients with PI, although adjusted estimates were imprecise. These findings suggest that pathological and MRI-based infiltrative markers may capture different and potentially complementary aspects of tumor behavior. External validation using standardized imaging and pathological review is required.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}